Antibody Conjugated Silk Nanoparticles for Targeted Doxorubicin Delivery in GBM

Names: Maddie Yost, Sabrina Zhang, Olivia Zeiden, Elysia Chang Faculty Advisor: Dr. David Kaplan Mentor: Sunny Shaidani



[0]

Project Goals



Determine the best receptor for targeting

I2 Establish the appropriate nanoparticle size for dosing and tumor uptake

Induce successful dual antibody conjugation

04 Determine the proper antibody quantity

Specific Aim 1: Develop dual antibody conjugated doxorubicin loaded silk nanoparticles

Specific Aim 2: Create 3D GBM model using transfected U87 cells Determine appropriate size, dose, and target receptors via lit review

Create product:

- 1. Process silk and load with doxorubicin during formation of nanoparticles
- 2. Conjugate chosen antibodies to loaded NP surfaces using EDC/NHS crosslinking

Characterize nanoparticles:

- 1. Quantify ratio of antibodies on NPs via fluorescent imaging
- 2. Ensure successful crosslinking of antibodies

Transfect U87 cells to express the two receptors of interest:

- 1. Infect cells with lentivirus carrying genes for receptors
- 2. Characterize cells to ensure receptor expression using western blot or ELISA

Seed transfected cells on silk sponges

Specific Aim 3: Characterize therapy efficacy Load nanoparticles onto the 3D GBM model:

- 1. Evaluate binding efficacy and nanoparticle uptake
- 2. Evaluate conditions of drug release
- 3. Measure levels of apoptosis using live/dead assay

Compare efficacy of dual-antibody, antibody A, and antibody B nanoparticles



What Has Been Done so Far

LITERATURE REVIEW

Glioblastoma Multiforme (GBM) vs Breast Cancer vs HCC

ANTIBODY RESEARCH

02

IL-13Ra2 vs EphA2 vs EphA3 vs EGFRviii

SILK PROCESSING

03

SciTech Room 166 (1 to 2 times a week for the past 3 weeks)

04

SILK NANOPARTICLES

SciTech Silk Nanoparticles Training led by Sunny

CELL CULTURE

05

Thawing, passaging, seeding U87s led by Maddie

Antibody Decision Matrix

Consideration	Weight	IL-13Ra2	EGFRviii	EPHA2
Expression in healthy tissue	5	3	5	3
Presence in GBM cells	5	5	3	4
Relevance/available background info	1	5	5	3
		45	45	38



Project Next Steps



Order Antibodies

Place an order for IL-13Ra2 and EGFRviii



Perform Literature Review to understand U87 transfection protocol



Once protocol determined, send registration to Biosafety Office



